Dow Up1.63% Nasdaq Up0.97%

Cepheid (CPHD)

46.45 1.78(3.98%) Oct 17, 4:00PM EDT
ProfileGet Profile for:
904 Caribbean Drive
Sunnyvale, CA 94089
United States - Map
Phone: 408-541-4191
Fax: 408-541-4192

Index Membership:N/A
Industry:Scientific & Technical Instruments
Full Time Employees:1,200

Business Summary 

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also provides GeneXpert Infinity System for high volume testing. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

Key Statistics

Company Websites 
Home Page
Investor Relations
Search Yahoo! for:
More on Cepheid

Corporate Governance 
Cepheid’s ISS Governance QuickScore as of Oct 1, 2014 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. John L. Bishop , 69
Chairman, Chief Exec. Officer and Member of Equity Incentive Committee
Mr. Thomas L. Gutshall , 76
Co-Founder, Director and Member of Nominating & Governance Committee
Mr. Andrew D. Miller , 53
Chief Financial Officer, Principal Accounting Officer and Exec. VP
Dr. Kerry J. Flom Ph.D., 62
Chief Regulatory Officer and Exec. VP
Mr. James Post , 51
Exec. VP of North American Commercial Operations
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders